

Case report

Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients

Bart Vrugt, Susan Wilson, Edwin van Velzen, Aad Bron, Janis K Shute, Stephen T Holgate, Ratko Djukanovic, René Aalbers

Abstract

Preliminary observations of the clinical efficacy of intravenous immunoglobulin in two patients with severe corticosteroid insensitive asthma are reported. In both patients treatment with intravenous immunoglobulin resulted in clinical improvement and enabled a significant reduction in the dose of prednisolone. In one of the patients fiberoptic bronchoscopy with endobronchial biopsies was performed and peripheral blood was analysed by flow cytometry before and after treatment. Immunohistological analysis of the biopsy samples after treatment showed a decrease in the number of all cell types, especially CD3+ T cells, CD4+ T cells, and activated CD25+ T lymphocytes, which was associated with a reduction in peripheral blood T cell activation. Intravenous immunoglobulin may be a valid option for the treatment of corticosteroid insensitive asthma. To elucidate the role and mode of action of intravenous immunoglobulin further studies in larger groups of patients are needed.

(Thorax 1997;52:662-664)

Keywords: asthma, intravenous immunoglobulin.

The use of intravenous immunoglobulin (Ig) in the treatment of severe asthma was found to be beneficial in one open study of clinical efficacy.¹ We treated two severe asthmatic patients who were found to be corticosteroid insensitive as judged by requirements of high doses of systemic corticosteroids, low pre-bronchodilator forced expiratory volume in one second (FEV₁) values (<70%), and decreased sensitivity of peripheral blood mononuclear cells to the inhibitory effects of dexamethasone *in vitro*.² In one of the patients we have de-

termined the effects of intravenous immunoglobulin treatment on T lymphocyte and eosinophil numbers and their state of activation in endobronchial biopsy specimens and peripheral blood. In the same patient we have investigated the ability of intravenous immunoglobulin to modulate the concentration of interleukin 8 (IL-8) and its IgG auto-antibodies in the circulation.

Case reports

CASE 1

A 15 year old girl with corticosteroid insensitive asthma was admitted to our hospital. On admission she was dyspnoeic at rest with a Cushingoid appearance. Lung function tests showed an obstructive pattern (FEV₁ 57%, forced vital capacity (FVC) 80%, airways resistance (Raw) 372% of predicted). Peak expiratory flow (PEF) variability was 65%. Total IgE was 2280 IU/l (normal <80 IU/l) with positive radio allergosorbent tests (RAST) for house dust mite and other aeroallergens.

Despite optimal treatment consisting of prednisolone (60 mg/day), inhaled budesonide (3000 µg/day), theophylline, and nebulised bronchodilators, her asthma proved difficult to control. Increasing the dose of oral prednisolone to 100 mg daily led to a modest decrease in PEF variability to 40%. Additional treatment with methotrexate did not result in clinical improvement or reduction of the dose of prednisolone, and was associated with considerable gastrointestinal side effects. After four weeks methotrexate was therefore discontinued (fig 1).

Treatment with intravenous immunoglobulin (Sandoglobulin, Sandoz, Bern, Switzerland) in a dosage of 84 g once a month (2 g/kg body weight) was commenced five months after admission. After two months of treatment there was a clear clinical improvement associated with a reduction in PEF variability to 10%, enabling the dose of prednisolone to be reduced to 10 mg/day. Mean morning PEF increased from 160 to 320 l/min, PEF variability decreased to 5%, and FEV₁ and FVC were 96% and 95% of predicted (fig 1).

CASE 2

The second patient, an 18 year old woman with a history of severe, poorly controlled asthma, was admitted to our institution in 1992 for evaluation and treatment. Since 1986 her asthma had been difficult to control with episodes of nocturnal symptoms and frequent emergency room visits. On admission we saw a dyspnoeic woman with Cushingoid features and FEV₁ of 51% predicted. Treatment consisted of prednisolone (30 mg/day), inhaled budesonide (2400 µg/day), formoterol, and nebulised bronchodilators. Increasing the dose of prednisolone to 90 mg/day did not lead to

Pathology Department, University Hospital Utrecht, Heidelberglaan 100, 3508GA Utrecht, The Netherlands
B Vrugt

Immunopharmacology Group, Medicine I, Southampton University, UK
S Wilson
J K Shute
S T Holgate
R Djukanovic

Dutch Asthma Centre, Davos, Switzerland
E van Velzen
A Bron
R Aalbers

Correspondence to: Dr B Vrugt.

Received 11 April 1996
Returned to authors 2 August 1996
Revised version received 18 October 1996
Accepted for publication 25 November 1996




Figure 1 Decrease in PEF variability (◆) and doses of prednisolone (■) in the two patients following treatment with intravenous immunoglobulin (▼). In case 1 * marks the introduction of methotrexate (15 mg/week).

clinical improvement (FEV₁ 58% of predicted).

In March 1993 intravenous immunoglobulin therapy (2 g/kg body weight/month) was introduced. Fibreoptic bronchoscopy with endobronchial biopsy samples and flow cytometric analyses of peripheral blood were performed before and after four months of treatment. During the period of treatment with intra-

venous immunoglobulin her medication was kept constant including oral prednisolone (90 mg/day) and inhaled budesonide (2400 µg/day). The mean asthma symptom score decreased from 8.9 to 5.1. PEF variability improved from 64.1% to 37.7%. Treatment with intravenous immunoglobulin was continued after the second bronchoscopy for a further two months during which oral prednisolone could be reduced from 90 to 25 mg/day while PEF variability improved further to 15% (fig 1). This was accompanied by an increase in FEV₁ from 68% of predicted before to 98% of predicted after six months of treatment. One year after intravenous immunoglobulin was introduced no exacerbations have occurred.

Immunohistological analysis of bronchial tissue after treatment with intravenous immunoglobulin revealed a decrease in the number of all cell types, especially CD3+ T cells, CD4+ T cells, and activated CD25+ T lymphocytes (table 1). Similarly, flow cytometric analysis of peripheral blood showed a decrease in CD3+ and CD4+ T cells bearing IL-2R and HLA-DR as well as reduced percentage of activated CD23+ B cells (table 1). Total serum IgE was decreased by 51% (from 3320 to 1622 IU/l) while IgG levels increased from 8.1 to 29.6 g/l (normal range 8–17 g/l). Free IL-8 was reduced by 72% (from 0.232 to 0.064 ng/ml), together with a 178% increase in IL-8/IgG complexes (from 0.061 to 0.170 units/ml) and a 28% increase in free IgG autoantibody (from 0.341 to 0.438 units/ml). Serum eosinophilic cationic protein (ECP), measured before and one week after the first infusion of intravenous immunoglobulin, showed a decrease from 34.6 µg/l (normal <16.0 µg/l) to undetectable levels and stayed undetectable throughout the remaining treatment period.

Discussion

In two patients with corticosteroid insensitive asthma treated with high doses of intravenous immunoglobulin we have observed a clear therapeutic benefit consisting of improved and long lasting control of asthma. This enabled a reduction in the dose of oral corticosteroids which in both patients was associated with significant morbidity. These observations are consistent with those of Mazer and Gelfand.¹

In the second case the improvement in airway inflammation was associated with a reduction in markers of disease activity in peripheral blood. Among the immunomodulating capacities of intravenous immunoglobulin, its potential to suppress T cell activation and B cell differentiation into antibody-secreting cells is relevant to asthma.³ Although the knowledge about the composition of intravenous immunoglobulin is incomplete and hence the action of the individual components unclear, soluble CD4, CD8, and HLA molecules have recently been detected in commercially available immunoglobulin preparations.⁴ It is possible that intravenous immunoglobulin exerts a therapeutic effect via interaction between soluble CD4 and HLA class II molecules on antigen-presenting cells, resulting in non-

Table 1 Results of immunohistological analyses of bronchial biopsy specimens and flow cytometric analyses of peripheral blood before and after treatment with intravenous immunoglobulin in case 2

| | Before | After | % change |
|--------------------------------------|--------|-------|----------|
| Biopsy specimen* | | | |
| Leucocytes (CD45) | 160 | 117 | -27 |
| T cells (CD3) | 116 | 84 | -28 |
| T helper cells (CD4) | 58 | 26 | -55 |
| T suppressor cells (CD8) | 25 | 20 | -20 |
| Interleukin 2 receptor (CD25) | 30 | 14 | -53 |
| Neutrophils (elastase) | 25 | 18 | -28 |
| Mast cells (tryptase) | 18 | 15 | -17 |
| Activated eosinophils (EG2) | 8 | 6 | -25 |
| Blood | | | |
| Leucocytes ($\times 10^6$ /ml) | 5.6 | 5.6 | 0 |
| Differential count | | | |
| Neutrophils (%) | 50 | 57 | 12 |
| Basophils (%) | 0 | 0 | 0 |
| Eosinophils (%) | 9 | 8 | -12 |
| Monocytes (%) | 8 | 6 | -25 |
| Lymphocytes (%) | 33 | 25 | -12 |
| Flow cytometry of lymphocytes | | | |
| CD3 (%) | 80 | 69 | -14 |
| CD4 (%) | 39 | 36 | -8 |
| CD4/CD25 (%)† | 7.1 | 1 | -86 |
| CD4/HLA-DR (%)† | 5.9 | 1 | -83 |
| CD8 (%) | 32 | 25 | -22 |
| CD8/CD25 (%)† | 0.5 | 0 | -100 |
| CD8/HLA-DR (%)† | 13.9 | 1 | -92 |
| CD19 (%) | 3 | 7 | 133 |
| CD19/CD23 (%)† | 68 | 56 | -18 |

*Number expressed as total cell count per mm² submucosa located beneath the basement membrane.

†Percentages of T and B lymphocytes expressing activation markers CD25 (IL-2R), HLA-DR (MHC class II), and CD23 (low affinity IgE receptor).

specific immunosuppression with decreased expression of IL-2R on T cells and subsequently reduced secretion of cytokines such as IL-4 and IL-5.

There is growing evidence that IL-8 plays an important role in the recruitment of inflammatory cells into the lungs of asthmatic subjects.⁵ Intravenous immunoglobulin may contain autoantibodies against cytokines, such as anti-IL-8 autoantibody, which neutralise their biological effects.⁶ The reduction in free IL-8 appears to result from its binding with the blocking IgG anti-IL-8 antibody present in intravenous immunoglobulin, a hypothesis that is supported by the substantial increase in IL-8/IgG complexes after treatment.

To clarify the role and mode of action of intravenous immunoglobulin in the treatment

of corticosteroid insensitive asthma, further studies in larger groups of patients are needed.

The authors would like to thank Sandoz Berne for the donation of intravenous immunoglobulins.

- 1 Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. *J Allergy Clin Immunol* 1991;**87**:976-83.
- 2 Corrigan CJ, Brown PH, Barnes NC, Szeffler SJ, Tsai J-J, Frew AJ, et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. *Am Rev Respir Dis* 1991;**144**:1016-25.
- 3 Hall PD. Immunomodulation with intravenous immunoglobulin. *Pharmacotherapy* 1993;**13**:564-73.
- 4 Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. *Lancet* 1993;**341**:789-90.
- 5 Shute J. IL-8 is a potent eosinophil chemoattractant. *Clin Exp Allergy* 1994;**24**:203-6.
- 6 Sylvester I, Yoshimura T, Sticherling M, Schröder J-M, Ceska M, Peichl P, et al. Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. *J Clin Invest* 1992;**90**:471-81.